DOO CHO: Open Payments
NPI 1609891662 · JOHNSTOWN, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,433 in 148 payments from 15 companies in 2025. Trend: 2023 $1,615 · 2024 $1,552 · 2025 $2,433
Food & beverage: $2,433
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $373 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $318 |
| E.R. Squibb & Sons, L.L.C. | 16 | $280 |
| Teva Pharmaceuticals USA, Inc. | 20 | $256 |
| Alkermes, Inc. | 13 | $207 |
| Janssen Pharmaceuticals, Inc | 12 | $206 |
| ABBVIE INC. | 16 | $201 |
| Neurocrine BioSciences, Inc. | 9 | $191 |
| Axsome Therapeutics, Inc. | 5 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
Products named: REXULTI, CAPLYTA, COBENFY, VRAYLAR, INGREZZA, ARISTADA, AUSTEDO XR, INVEGA SUSTENNA.
Industry payments across PA — which companies pay providers there.
